• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
404 Not Found

Not Found

The requested URL /esi/auxiliary-nav.html was not found on this server.

Additionally, a 404 Not Found error was encountered while trying to use an ErrorDocument to handle the request.

Pharmaceutical

About

Pharmaceutical is part of our work in Life Sciences.

Breakthrough discoveries and innovations require strong protection

People rely on the pharmaceutical industry for life-saving drugs and treatments, as well as those that improve the quality of life. Even with billions of dollars invested in research and development, few drugs make it through clinical trials and stringent regulatory clearances necessary to get to market. For those that do, it is crucial that the companies have protected the intellectual property (IP) underlying new drugs and treatments. Finnegan has a long history of working with innovative pharmaceutical companies to protect and maximize their valuable IP rights and assets, strategizing prosecution pathways and portfolio planning.

Understanding the law, science, and technology

Our clients’ business and IP assets are global; protecting these assets across jurisdictions is increasingly challenging. With offices around the world and experience with multinational companies, Finnegan has the resources and experience to formulate and execute global strategies for pharmaceutical companies. The fast pace of new discoveries and their commercial applications require a comprehensive grasp of the IP legal issues and the industry insight to understand the scientific and strategic implications of the advancements.

With experience addressing virtually every type of IP issue for our pharmaceutical clients, we help by:

  • Representing clients in complex pharmaceutical patent infringement and trade secret cases, including Hatch-Waxman litigation
  • Litigating high value products in district and appellate courts with experienced trial and appellate teams
  • Developing and executing prosecution strategies to both protect a client’s products and analyze those of its competitors, thus helping ensure that the client realizes value from its IP assets
  • Preparing and negotiating licenses, assessing the licensing value of competitors’ patents, and guiding clients in decisions to license 
  • Providing due diligence for merger and acquisition and partnership targets 
  • Providing counsel on business-related matters, including antitrust and competition issues 
  • Determining priority in complex interferences 
  • Advising on potential litigation strategies, and asserting and defending patents in court
  • Providing trademark prosecution and counseling services 

We work with clients innovating and advancing science in myriad fields, including:

  • Antibody therapies—small and large molecules 
  • Atypical antipsychotic drugs
  • Sustained-release formulations 
  • Vaccines 

 

Contacts

Everyone in this industry

Experience

Arbitration victory for major U.S. pharmaceutical company
Represented a major U.S. pharmaceutical company in two arbitrations concerning a leading biologic. Finnegan’s client won both arbitrations and, in the second, was awarded its attorney fees.
BCL-2 inhibitors licensing agreement for Fochon Pharmaceuticals, Ltd.
Drafted and negotiated a complex license agreement for Fochon Pharmaceuticals, Ltd. relating to BCL-2 inhibitors with up to $400 million in potential development and commercial milestones.
Finnegan successfully represents U.S. pharmaceutical company in an arbitration
Represented a U.S. pharmaceutical company in an arbitration with a former consultant and inventor. The dispute involved issues relating to inventorship and ownership, as well as the determination of royalties due under various agreements. The matter settled shortly before the hearing on favorable terms.
Lipid nanoparticle licensing and collaboration agreements for Genevant Sciences
Represented Genevant Sciences in negotiating and drafting several license and collaboration agreements for Genevant’s lipid nanoparticle technology, including agreements with Gritstone Oncology relating to COVID-19 and BioNTech relating to development of mRNA therapeutics for rare diseases.
Multiple settlement and license agreements for AbbVie, Inc.
Assisted AbbVie, Inc. with multiple settlement and license agreements relating to a leading biopharmaceutical product.
Small molecule product development agreement for Roivant Sciences
Drafted and negotiated a complex strategic development agreement for Roivant Sciences relating to a small molecule product with potential payments of up to $600 million.

164 More

Insights

Seminar

Legal Career Elite Charity Training Camp

April 28, 2021

Shanghai

Webinar

Recent Pharmaceutical, Chemical, and Biotech Patent Case Law on Infringement Under the Doctrine of Equivalents

April 22, 2021

Webinar

Webinar

Patenting AI Inventions for the Healthcare and Pharmaceutical Industries

April 7, 2021

Webinar

At the PTAB Blog

Federal Circuit: Mandamus Petitions Challenging Institution Denial Are Unlikely to Show Right to Relief

March 31, 2021

Federal Circuit IP Blog

§ 314(d) Bar Does Not Defeat Federal Circuit’s Mandamus Jurisdiction

March 29, 2021

At the PTAB Blog

In Rare Sua Sponte Order, PTAB Finds Using a Trademark Could Render Claim Indefinite

March 17, 2021

507 More

Upcoming Events

Conference

Biolign Innovators World 2021

June 6-10, 2021

Suzhou

Seminar

Legal Career Elite Charity Training Camp

April 28, 2021

Shanghai

Webinar

Recent Pharmaceutical, Chemical, and Biotech Patent Case Law on Infringement Under the Doctrine of Equivalents

April 22, 2021

Webinar

News

Commentary

How 2020 ANDA Litigation Played Out – and What to Expect for 2021

March 25, 2021

Commentary

How I Made Partner: Finnegan's Danielle Duszczyszyn Shares Six Keys to Business Development Success

December 16, 2020

Press Release

Finnegan Celebrates Two Wins at the 2020 LMG Life Sciences Awards and Top Honors in the Rankings

October 5, 2020

Announcement

Margaret Esquenet Wins “Best in Copyright” at Women in Business Law Awards

September 22, 2020

Media Mention

Finnegan Shortlisted for 2020 LMG Life Sciences Awards

August 4, 2020

Commentary

Rush for Generic Go-Ahead on Novel Drugs Roils Pharma Industry

June 19, 2020

120 More

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP